Inhibition of respiratory viruses by nasally administered siRNA
By V. Bitko, A. Musiyenko, Olena Shulyayeva, S. Barik. Nature Medicine, 2005
751 citations recorded by the source corpus.
Subfields: Animal Science and Zoology, Epidemiology, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/8925a7bfe215f9109cd570e7e3fe5a1b8b3e5c22
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Animal Science and Zoology
In Epidemiology
In Molecular Biology
- Robert Langer
- Daniel G. Anderson
- P. McCray
- Peter S. Linsley
- J. Lieberman
- M. Manoharan
- D. Dykxhoorn
- Kathryn A. Whitehead
Citations in the corpus
- Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors (2005, background): “An exception may be pulmonary epithelial cells, since protection against respiratory syncytial virus infection in the lung was achieved in one report by nasal administration of siRNAs without any transfection reagen”
- Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application (2010, background): “However, data describing competition between siRNAs, in which co-delivery of multiple siRNAs reduced efficacy of each individual reagent, suggest that siRNAs are able to saturate some components of the cellular RNAi machiner”
- Knocking down barriers: advances in siRNA delivery (2009, background): “It is no coincidence that much of the successful siRNA delivery seen in recent years has targeted disease within these organs 4, 29, 30, 57, 58 .”
- Current prospects for RNA interference-based therapies (2011, background): “In 2004 and 2005 several high-profile papers were published in which synthesized siRNAs or expressed shRNAs were used to inhibit the influenza A virus 92,93 , severe acute respiratory syndrome (SARS) coronavirus 94 , respiratory syncytial virus 4,94 and parainfluenza virus in animal models 4 .”
- The promises and pitfalls of RNA-interference-based therapeutics (2009, neutral): “Intranasal delivery has proved an effective means of delivering siRNA in mic”
- RNAi therapeutics: a potential new class of pharmaceutical drugs (2006, background): “Local RNAi can protect against both respiratory 42, 9 and vaginal 43 viral infections.”
- Lipid-like materials for low-dose, in vivo gene silencing (2010, background): “In some applications, effective delivery of naked siRNAs, without a carrier, may be possible (6, 7).”
- A combinatorial library of lipid-like materials for delivery of RNAi therapeutics (2008, background): “Certain viruses, such as respiratory syncytial virus can be inhibited locally after administration of naked siRN”